FDA Approves First Ready-to-Use Stable Liquid Glucagon for Severe Hypoglycemia
In the House: How Inpatient Diabetes Teams Can Improve Patient Outcomes and Reduce Costs
FDA Approves First Treatment for Severe Hypoglycemia That Can Be Administered without an Injection
In July, the U.S. Food and Drug Administration approved a nasal powder glucagon therapy for the emergency treatment of severe hypoglycemia that can be administered without an injection. Eli Lilly and Company is marketing the drug as Baqsimi. The therapy has been approved to treat severe hypoglycemia in patients with diabetes ages four and older....CEU Preview: Challenging Cases in Lipid Management with Lisa Tannock, MD
Next month, the Endocrine Society’s Clinical Endocrinology Update will kick off in Miami, during which attendees will hear about the latest breakthroughs in patient care, as well as those cases that may prove difficult for clinicians. One such session is Lisa Tannock’s Meet-the-Professor presentation on Thursday, September 5, titled “Challenging Cases in Lipid Management.” Cardiovascular...Clinical Endocrinology Update Goes Bicoastal for a Second Year
After the success of last year’s special issue to promote and highlight the Endocrine Society’s Clinical Endocrinology Update (CEU) program, we decided to make it an annual tradition. For the second year in a row, CEU will take place twice in the September on both the East and West Coasts — Sept. 5 – 7... The advent of newer — often very expensive — drugs has driven up the cost of care for diabetes. But older, less expensive medications can often still get the job done. Treating diabetes with lower-cost drugs might not only help a patient’s pocketbook, they might benefit the patient’s health as well. That will be one...
